[go: up one dir, main page]

HK1010050A1 - The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy - Google Patents

The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy Download PDF

Info

Publication number
HK1010050A1
HK1010050A1 HK98110478A HK98110478A HK1010050A1 HK 1010050 A1 HK1010050 A1 HK 1010050A1 HK 98110478 A HK98110478 A HK 98110478A HK 98110478 A HK98110478 A HK 98110478A HK 1010050 A1 HK1010050 A1 HK 1010050A1
Authority
HK
Hong Kong
Prior art keywords
salt
pharmaceutically acceptable
composition
formula
solvate
Prior art date
Application number
HK98110478A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1010050B (en
Inventor
Baker Raymond
G. Pitt Kendal
G. Matassa Victor
Olive Carole
E. Storey David
J. Street Leslie
Richard Guiblin Alexander
Original Assignee
Merck Sharp & Dohme Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211903A external-priority patent/GB9211903D0/en
Priority claimed from GB939307306A external-priority patent/GB9307306D0/en
Application filed by Merck Sharp & Dohme Ltd. filed Critical Merck Sharp & Dohme Ltd.
Publication of HK1010050B publication Critical patent/HK1010050B/en
Publication of HK1010050A1 publication Critical patent/HK1010050A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
HK98110478A 1992-06-05 1998-09-05 The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy HK1010050A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9211903 1992-06-05
GB929211903A GB9211903D0 (en) 1992-06-05 1992-06-05 Pharmaceutical composition
GB939307306A GB9307306D0 (en) 1993-04-07 1993-04-07 Therapeutic agents
GB9307306 1993-04-07

Publications (2)

Publication Number Publication Date
HK1010050B HK1010050B (en) 1999-06-11
HK1010050A1 true HK1010050A1 (en) 1999-06-11

Family

ID=26301005

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98110478A HK1010050A1 (en) 1992-06-05 1998-09-05 The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy

Country Status (27)

Country Link
US (1) US5527817A (fi)
EP (1) EP0573221B1 (fi)
JP (2) JP2619197B2 (fi)
KR (1) KR100286411B1 (fi)
CN (1) CN1043532C (fi)
AT (1) ATE165602T1 (fi)
AU (2) AU659311B2 (fi)
BG (1) BG61976B1 (fi)
CA (1) CA2097208C (fi)
CZ (1) CZ282060B6 (fi)
DE (1) DE69318212T2 (fi)
DK (1) DK0573221T3 (fi)
ES (1) ES2116411T3 (fi)
FI (3) FI106201B (fi)
HK (1) HK1010050A1 (fi)
HU (1) HUT71403A (fi)
IL (1) IL105847A (fi)
LV (1) LV12210B (fi)
MX (1) MX9303373A (fi)
NO (1) NO307420B1 (fi)
NZ (1) NZ253210A (fi)
RO (1) RO114326B1 (fi)
RU (1) RU2130022C1 (fi)
SG (1) SG50406A1 (fi)
SK (1) SK279211B6 (fi)
UA (1) UA27908C2 (fi)
WO (1) WO1993025547A1 (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282060B6 (cs) * 1992-06-05 1997-05-14 Merck Sharp And Dohme Limited Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
WO1997003068A1 (en) * 1995-07-11 1997-01-30 Merck & Co., Inc. A triazolylmethyl-indole ethylamine bisulfate salt
US6192882B1 (en) * 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
JP2002528498A (ja) * 1998-11-02 2002-09-03 メルク エンド カムパニー インコーポレーテッド 片頭痛の治療方法及び医薬組成物
EP2332934B1 (en) 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
ES2270717B1 (es) * 2005-08-08 2008-03-01 Ragactives, S.L. Procedimiento para la obtencion de derivados de triptamina.
WO2007054979A1 (en) * 2005-11-14 2007-05-18 Matrix Laboratories Ltd Process for the large scale production of rizatriptan benzoate
CA2688463A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Process for the preparation of rizatriptan
WO2017130141A1 (en) 2016-01-27 2017-08-03 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
WO2024144413A1 (ru) * 2022-12-28 2024-07-04 Общество С Ограниченной Ответственностью "Ферринг Продакшн" Жидкая фармацевтическая композиция для назального введения, содержащая ризатриптан

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528319A3 (ru) * 1985-07-23 1989-12-07 Глэксо Груп Лимитед (Фирма) Способ получени производных имидазола или их физиологически приемлемых солей
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
KR920011020B1 (ko) * 1989-07-03 1992-12-26 요시또미세이야꾸 가부시끼가이샤 벤즈아진 화합물 및 그의 의약용도
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
CZ282060B6 (cs) * 1992-06-05 1997-05-14 Merck Sharp And Dohme Limited Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby

Also Published As

Publication number Publication date
UA27908C2 (uk) 2000-10-16
NO944656D0 (no) 1994-12-02
CZ304494A3 (en) 1995-09-13
RO114326B1 (ro) 1999-03-30
FI20001776A7 (fi) 2000-08-10
US5527817A (en) 1996-06-18
LV12210B (en) 1999-03-20
SK147994A3 (en) 1995-07-11
AU4337293A (en) 1994-01-04
BG99132A (bg) 1995-07-28
JP2972150B2 (ja) 1999-11-08
KR100286411B1 (ko) 2001-04-16
BG61976B1 (bg) 1998-11-30
SG50406A1 (en) 1998-07-20
CN1089263A (zh) 1994-07-13
JPH09176155A (ja) 1997-07-08
RU2130022C1 (ru) 1999-05-10
ES2116411T3 (es) 1998-07-16
FI20001777A7 (fi) 2000-08-10
NZ253210A (en) 1995-09-26
EP0573221B1 (en) 1998-04-29
IL105847A0 (en) 1993-09-22
LV12210A (lv) 1999-01-20
HU9403478D0 (en) 1995-02-28
KR950701922A (ko) 1995-05-17
NO944656L (no) 1994-12-02
DK0573221T3 (da) 1998-10-07
CA2097208A1 (en) 1993-12-06
MX9303373A (es) 1995-01-31
DE69318212D1 (de) 1998-06-04
AU3987593A (en) 1993-12-09
SK279211B6 (sk) 1998-08-05
FI945694A0 (fi) 1994-12-02
WO1993025547A1 (en) 1993-12-23
CZ282060B6 (cs) 1997-05-14
NO307420B1 (no) 2000-04-03
DE69318212T2 (de) 1998-11-19
EP0573221A1 (en) 1993-12-08
FI106201B (fi) 2000-12-15
FI20001776L (fi) 2000-08-10
AU659311B2 (en) 1995-05-11
FI20001777L (fi) 2000-08-10
RU94046380A (ru) 1996-12-10
HUT71403A (en) 1995-11-28
JPH0641121A (ja) 1994-02-15
CN1043532C (zh) 1999-06-02
JP2619197B2 (ja) 1997-06-11
FI945694L (fi) 1994-12-02
CA2097208C (en) 2005-02-08
IL105847A (en) 1998-09-24
ATE165602T1 (de) 1998-05-15

Similar Documents

Publication Publication Date Title
US5554639A (en) Medicaments
EP0573221B1 (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
HK1010050B (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
US5834502A (en) Triazolylmethyl-indole ethylamine bisulfate salt
CA2225416C (en) A triazolylmethyl-indole ethylamine bisulfate salt
HRP940225A2 (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)